Colorectal cancer (CRC) is one of the leading causes of cancer-related morbidity and mortality worldwide, making timely screening a public health priority. Screening modalities such as colonoscopy and stool tests have been shown to reduce both incidence and mortality by detecting precancerous lesions and early-stage cancers. Nevertheless, screening rates remain suboptimal across many populations, prompting researchers and healthcare professionals to explore innovative strategies to enhance participation.

The study, conducted by researchers affiliated with Indiana University, enrolled 214 primary care providers and 1,084 average-risk patients aged 50 to 75 years who were overdue for CRC screening. The investigators sought to assess whether the delivery of personalized risk messages about ACN to both patients and their providers could positively influence the completion of screening tests within six months. The trial design incorporated both patient-facing and provider-targeted interventions, leveraging decision aids and notifications, respectively.

Patients were randomized to receive either a generic decision aid on CRC screening or a personalized one that integrated their individual ACN risk assessment. Simultaneously, providers were randomized to receive either generic notifications about their patients’ screening status or personalized notifications incorporating the same risk data. This factorial design permitted evaluation of the isolated and combined effects of personalized communication on CRC screening adherence.

Despite the theoretical appeal, the intervention failed to demonstrate a statistically significant impact. Approximately 39.8% of participants completed screening within six months, a rate consistent across all study arms regardless of the personalization of messages. This outcome suggests that simply adding individualized cancer risk information to standard communication tools may not overcome barriers to screening, such as logistical challenges, health beliefs, or systemic factors within healthcare delivery.

The findings confront an important question in preventive medicine: how can screening uptake be meaningfully improved beyond existing approaches? Personalized risk messaging has been lauded for its potential to resonate more powerfully with individuals by honing in on their unique health profiles. However, the null results here indicate that risk messages alone might be insufficient to change patient or provider behavior in colorectal cancer screening.

Several potential explanations exist for these findings. First, recipients may not have fully understood or trusted the personalized risk information, limiting its influence. Health literacy and numeracy play critical roles in how patients interpret such messages, and without adequate support, the added complexity might have even led to confusion or disengagement. On the provider side, competing clinical priorities, limited time, and alert fatigue could blunt the impact of additional personalized notifications.

Moreover, patient decisions around CRC screening are multifactorial, influenced by psychological, social, and economic considerations that risk messaging alone does not address. Factors such as perceived inconvenience of colonoscopy, concerns about discomfort or complications, lack of insurance coverage, and cultural attitudes toward cancer screening remain powerful determinants of behavior. The study’s outcome underscores the necessity for multifaceted interventions combining personalized communication with system-level enablers and behavioral support mechanisms.

In light of these results, further research is crucial to refine strategies that genuinely mobilize patients and providers toward screening adherence. Future trials may need to integrate personalized risk communication into broader frameworks incorporating counseling, navigation services, and improved access to screening modalities. Additionally, tailoring messages not only by clinical risk but also by psychosocial determinants might enhance relevance and motivation.

Beyond colorectal cancer screening, these findings bear implications for personalized medicine approaches across preventive health domains. The promise of risk stratification and individualized messaging is immense, but this study serves as a sobering reminder that information alone does not automatically translate to action. Behavioral science insights and patient engagement principles must guide the development of future interventions.

The study also highlights the importance of rigorous evaluation of digital health tools and communication strategies before widescale implementation. Personalized decision aids and risk notifications represent resource-intensive investments, and their clinical and economic value must be justified through evidence of efficacy.

In conclusion, while personalized risk messages appear intuitive as catalysts for health behavior change, this randomized controlled trial shows they do not significantly boost colorectal cancer screening uptake in an average-risk population. Healthcare systems aiming to increase CRC screening rates should consider comprehensive, multifaceted approaches rather than relying solely on personalized communication. The ongoing challenge remains to design interventions that effectively translate awareness and motivation into action, ultimately reducing the burden of colorectal cancer.

Research correspondence and embargoed requests can be directed to the study authors and media contacts affiliated with the American College of Physicians and Indiana University, underscoring the importance of collaboration between academic institutions and professional organizations in advancing preventive medicine.

Subject of Research: People
Article Title: Impact of Personalized Risk Messages on Uptake of Colorectal Cancer Screening: A Randomized Controlled Trial
News Publication Date: 2-Sep-2025
Web References: http://dx.doi.org/10.7326/ANNALS-24-03144
Keywords: Colorectal cancer, Risk communication, Cancer screening

Cardiometabolic disease encompasses a constellation of interrelated conditions including obesity, insulin resistance, type 2 diabetes, and cardiovascular disease. These disorders collectively constitute the leading cause of mortality among women in the United States, with Black women experiencing the cruelest burden due to socioeconomic disparities and systemic healthcare inequities. Despite the stark statistics, they remain critically underrepresented in clinical trials exploring preventive and therapeutic interventions. This study thus addresses a glaring gap by investigating whether a non-pharmacological, culturally adaptable intervention like TM can induce measurable, sustained improvements in metabolic health.

Central to cardiometabolic pathology is insulin resistance, a condition wherein cellular sensitivity to insulin diminishes, leading to dysregulated glucose homeostasis and chronic hyperglycemia. Clinically, hemoglobin A1c (HbA1c) serves as a biomarker reflecting average blood glucose over three months and is instrumental in diagnosing and monitoring diabetes. In this trial, TM practitioners exhibited statistically significant reductions in HbA1c compared to the health education control group, implying improved glycemic control. Furthermore, insulin sensitivity, evaluated via the Homeostatic Model Assessment of Insulin Resistance (HOMA-IR), improved markedly in the meditation cohort. These changes highlight TM’s potential to favorably influence metabolic pathways disrupted in prediabetes and diabetes.

The physiological mechanisms by which Transcendental Meditation exerts such effects are multifaceted and intertwined with neuroendocrine and autonomic regulation. Chronic psychosocial stress activates the hypothalamic-pituitary-adrenal (HPA) axis and sympathetic nervous system, culminating in elevated cortisol and catecholamine levels that exacerbate insulin resistance, systemic inflammation, and endothelial dysfunction. TM fosters a state of restful alertness that attenuates stress responses, thereby lowering circulating stress hormones. This modulation may reverse or blunt the cascade of pathophysiological processes that propel metabolic syndrome and vascular complications, as supported by observed decreases in arterial stiffness and inflammatory markers in prior studies.

In addition to glycemic parameters, the study reported improvements in lipid profiles, particularly an increase in high-density lipoprotein (HDL) cholesterol, colloquially known as “good cholesterol.” Elevated HDL is cardioprotective, facilitating reverse cholesterol transport and reducing atherosclerotic plaque formation. This finding is critical given the elevated cardiovascular mortality risk in Black women. Complementing biochemical improvements, participants practicing TM experienced nearly 5% weight loss within a year, a clinically meaningful reduction that independently lowers diabetes and cardiovascular risks. Importantly, this weight loss occurred without overt changes in prescribed diet or exercise regimens, underscoring meditation’s influence on metabolic regulation beyond traditional lifestyle approaches.

As contemporary medicine witnesses a surge in interest around GLP-1 receptor agonists like Ozempic and Wegovy for weight and glycemic management, the study provides a crucial perspective on complementary interventions. Unlike pharmacotherapies, which often require costly, ongoing medical supervision and may bear adverse effects, TM is low-cost, scalable, and devoid of side effects. This positions meditation as an accessible modality, especially for underserved communities with limited healthcare access—a factor that could help bridge existing health equity chasms intensified by socioeconomic determinants.

The significance of this research transcends clinical metrics; it champions an integrative health paradigm that acknowledges the psychosocial underpinnings of metabolic diseases. By harnessing mind-body techniques that modulate stress physiology and metabolic pathways, healthcare practitioners can adopt a holistic strategy in combating the burgeoning epidemics of diabetes and cardiovascular disease. Such approaches align with contemporary public health calls for interventions that are culturally relevant, patient-centered, and sustainable within community contexts.

In terms of study design, the randomized controlled trial enrolled 201 women from two urban academic medical centers, randomized to receive either standard health education or Transcendental Meditation instruction, with adherence and outcomes assessed over 12 months. The rigorous methodology including blinding of outcome assessors and validated biomarker measurements enhances the reliability of findings. Crucially, the collaboration across institutions ensured culturally competent implementation and recruitment strategies, which likely contributed to the high retention rates and intervention fidelity observed.

Leading the research, Dr. Carolyn Gaylord-King from Maharishi International University emphasized the unprecedented timing of these results amidst escalating chronic disease prevalence. “These findings underscore meditation’s utility as a practical, non-pharmacologic intervention that could be integrated into existing healthcare frameworks to curtail metabolic disease progression,” she stated. Co-investigator Dr. Charlie Harris highlighted the health equity impact, noting that addressing stress-related metabolic dysregulation in Black women fills a critical prevention research void.

This study also reinforces prior evidence linking mind-body medicine to cardiometabolic outcomes, extending it by focusing specifically on a high-risk demographic often excluded from trials. While TM is not intended to supplant medical treatment, its incorporation alongside pharmacological and lifestyle interventions could amplify therapeutic benefits. The biological plausibility, supported by neuroendocrine, inflammatory, and autonomic modulation, offers a strong mechanistic foundation for observed clinical improvements.

Given the staggering economic burden and human cost of cardiometabolic diseases, innovative, accessible preventive strategies are urgently needed. Integrating meditation into public health strategies holds promise for reducing healthcare costs by preventing disease onset or mitigating severity. Furthermore, the scalability of TM training via group sessions or digital platforms enhances feasibility, making it an attractive adjunct in community health initiatives targeting social determinants.

In conclusion, this landmark investigation propels Transcendental Meditation into the spotlight as a scientifically validated, culturally sensitive intervention with potent effects on critical metabolic health indicators in older Black women. By attenuating underlying stress pathways implicated in insulin resistance and cardiovascular risk, TM offers a transformative avenue for enhancing health equity and combating the nation’s cardiometabolic crisis. Future research expanding sample sizes and exploring long-term cardiovascular event outcomes will be pivotal in cementing meditation’s role within comprehensive disease prevention paradigms.

Subject of Research: People

Article Title: A Multicenter Randomized Controlled Trial of Meditation and Health Education in the Prevention of Cardiometabolic Disease in Black Women

News Publication Date: 1-Aug-2025

Web References:
https://www.liebertpub.com/doi/10.1177/15409996251364663

References: Published article in Journal of Women’s Health

Image Credits: Maharishi International University

Keywords: Transcendental Meditation, insulin resistance, HbA1c, cardiometabolic disease, Black women health disparities, randomized controlled trial, mindfulness, stress reduction, diabetes prevention, obesity, HDL cholesterol, neuroendocrine modulation

This comprehensive phase II randomized controlled trial enrolled 102 adults diagnosed with moderate to severe alcohol use disorder. Participants were administered either ibudilast or a placebo twice daily over a 12-week treatment period, followed by a four-week monitoring phase. The study meticulously measured several drinking behavior metrics including the percentage of heavy drinking days, average drinks per drinking day, and percent days abstinent. Additionally, assessments of depressive symptoms and inflammatory biomarkers were integrated to understand the differential biological and psychological responses to treatment.

The overarching result was sobering: ibudilast did not significantly outperform placebo across the entire cohort in reducing alcohol consumption. Both groups exhibited a meaningful decline in drinking levels over the treatment span, with the average number of drinks per drinking day dropping from approximately seven to between three and four. This robust placebo effect highlights an entrenched challenge in addiction medicine research — the difficulty in disaggregating true pharmacological effects from the multifaceted psychosocial influences and expectancy effects inherent in clinical trial settings.

Notwithstanding the overall null findings, the study unveiled a compelling sex-specific response pattern. Female participants exhibited a statistically significant reduction in drinks per drinking day when treated with ibudilast compared to placebo. This differential efficacy aligns with emerging data that women generally manifest higher basal levels of systemic inflammation than men, possibly making them more responsive to treatments targeting neuroimmune pathways. The observation that ibudilast’s anti-inflammatory actions may underlie this sex-dependent benefit marks an important development in understanding AUD’s heterogeneity and tailoring personalized treatment protocols.

Conversely, participants presenting with elevated depressive symptoms at baseline paradoxically fared worse on ibudilast compared to placebo. This complex interaction between mood disorders and immune-modulating pharmacotherapies underscores the intricate neurobiological interplay between psychiatric comorbidities and addiction. Depression’s known association with dysregulated immune signaling might modulate drug efficacy negatively, suggesting that co-occurring psychiatric profiles are critical variables in assessing candidate AUD medications and require careful stratification in future trials.

Despite targeting neuroimmune mechanisms, ibudilast did not significantly reduce peripheral biomarkers of inflammation in this study. This unexpected outcome raises pivotal questions about the drug’s mechanism of action in the context of AUD and the adequacy of measuring systemic inflammatory markers to infer central nervous system effects. The blood-brain barrier’s selective permeability and regional neuroimmune dynamics may mean that peripheral inflammatory assays inadequately capture the nuanced immunomodulatory processes relevant to addiction pathophysiology.

The trial’s investigators, led by UCLA psychology professor Lara Ray, emphasized the necessity of longer-duration studies to further distinguish the sustained effects of ibudilast from initial placebo-mediated improvements. Treatment efficacy in AUD often requires extended evaluation beyond conventional 12-week trials to observe enduring decreases in alcohol use and relapse prevention. Indeed, the current findings advocate for larger, sex-stratified studies with prolonged follow-ups to better elucidate ibudilast’s therapeutic potential and target populations.

Importantly, this research reiterates the emerging paradigm that immune system dysregulation plays a significant role in substance use disorders. Neuroinflammation is increasingly recognized as a crucial contributor to the neurocircuitry alterations that reinforce compulsive alcohol consumption. The possibility that immunomodulatory agents such as ibudilast and apremilast could revolutionize AUD treatment mirrors the transformative effects these therapies have had in oncology, where targeting immune checkpoints has reshaped clinical outcomes.

Moreover, the results highlight the critical importance of integrating multidimensional phenotyping, including inflammatory status and psychiatric comorbidities, in clinical trials for addiction medications. Personalized medicine approaches, guided by biomarker profiles and symptomatic clusters, could optimize therapeutic outcomes by matching patients with interventions tailored to their neuroimmune and emotional landscapes.

The trial’s robust methodology, carefully tracking drinking behaviors alongside psychological and biological parameters, provides a rich dataset for ongoing analyses. Future investigations promise to clarify which subpopulations, such as individuals with comorbid chronic pain or elevated inflammation, might gain the most from ibudilast treatment. These precision medicine insights are expected to shape the next wave of innovation in AUD therapeutics, moving beyond one-size-fits-all approaches.

While the disappointing overall lack of superiority over placebo underscores the formidable challenges in developing pharmacotherapies for alcohol use disorder, the positive signals observed in women inject cautious optimism. They prompt a reevaluation of neuroimmune targets and gender-specific biology in addiction science. As Professor Ray notes, understanding who responds and why remains an imperative scientific quest, one with profound implications given that nearly 30 million adults in the United States suffer from AUD.

The trial was supported by the National Institute on Alcohol Abuse and Alcoholism, reflecting sustained federal commitment to combating a pervasive and costly public health issue. As laboratories worldwide continue to explore the interface of neuroimmunology and addiction, the nuanced findings from the UCLA Addictions Lab’s ibudilast study serve as both a cautionary tale and a beacon guiding future inquiry. With innovative trial designs, biomarker integration, and longer follow-up periods, the path forward appears promising, offering hope for novel, effective medications for those battling the disease of alcoholism.

Ultimately, the translation of immune-targeting therapies from cancer immunotherapy to psychiatric conditions like AUD represents a frontier of neuropsychopharmacology. While ibudilast’s journey from hopeful candidate to nuanced outcome illustrates the complexity of addiction biology, it also expands our conceptual frameworks. The ongoing quest to disentangle the neuroimmune contributions to alcohol use disorder continues, underscoring the dynamism and rigor required to develop transformative treatments that can reduce the massive societal burden of addiction.

Subject of Research: Alcohol Use Disorder treatment; Neuroimmune modulation; Ibudilast clinical trial

Article Title: Not provided in the original content

News Publication Date: Not explicitly stated; article references publication in JAMA Network Open

Web References:

• UCLA Addictions Lab: https://addictions.psych.ucla.edu/
• JAMA Network Open article: https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2833329
• Prior ibudilast research: https://addictions.psych.ucla.edu/wp-content/uploads/sites/160/2018/01/NPP-Development-of-the-neuroimmune-modulator-ibudilast-for-the-treatment-of-alcoholism-A-randomized-placebo-controlled-human-laboratory-trial.pdf OR https://pubmed.ncbi.nlm.nih.gov/34585396/

References: Included research articles as above

Image Credits: Not provided

Keywords: Alcoholism, Substance related disorders, Addiction, Asthma, Health and medicine